DOT1L Protein

DOT1L Protein — Histone H3K79 Methyltransferase

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DOT1L Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Disruptor of Telomeric Silencing 1-like</td></tr>
<tr><td><strong>Gene</strong></td><td>[DOT1L](/genes/dot1l)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8TEZ3](https://www.uniprot.org/uniprot/Q8TEZ3)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3UVW, 4ER5, 5X3O</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~190 kDa (1,677 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus (chromatin-associated)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Histone methyltransferase (non-SET family)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>High in cortex, hippocampus, and cerebellum</td></tr>
<tr><td><strong>Domain Architecture</strong></td><td>N-terminal chromatin-binding domain, C-terminal catalytic domain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/covid" style="color:#ef9a9a">Covid</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">92 edges</a></td>
</tr>
</table>
</div>

DOT1L Protein — Histone H3K79 Methyltransferase

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DOT1L Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Disruptor of Telomeric Silencing 1-like</td></tr>
<tr><td><strong>Gene</strong></td><td>[DOT1L](/genes/dot1l)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8TEZ3](https://www.uniprot.org/uniprot/Q8TEZ3)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3UVW, 4ER5, 5X3O</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~190 kDa (1,677 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus (chromatin-associated)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Histone methyltransferase (non-SET family)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>High in cortex, hippocampus, and cerebellum</td></tr>
<tr><td><strong>Domain Architecture</strong></td><td>N-terminal chromatin-binding domain, C-terminal catalytic domain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/covid" style="color:#ef9a9a">Covid</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">92 edges</a></td>
</tr>
</table>
</div>

Overview

DOT1L (Disruptor of Telomeric Silencing 1-like) is a unique histone methyltransferase that catalyzes the methylation of histone H3 at lysine 79 (H3K79)[@freitas2024]. Unlike the majority of histone methyltransferases that belong to the SET domain family, DOT1L represents a distinct class of methyltransferases with remarkable structural and functional properties. The enzyme adds mono-, di-, and trimethylation marks to H3K79, a modification that plays critical roles in transcriptional regulation, DNA damage response, cell cycle progression, and development[@kouzarides2007].

The discovery of DOT1L's involvement in MLL-rearranged leukemia has made it a major therapeutic target in oncology, with several DOT1L inhibitors currently in clinical development[@okada2005]. Beyond its well-established role in hematological malignancies, emerging evidence suggests that DOT1L and H3K79 methylation are crucial for proper neuronal development, synaptic plasticity, and cognitive function. Dysregulation of this epigenetic pathway has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@mukherjee2021; @wu2020].

This comprehensive page covers DOT1L's molecular structure, its normal functions in the nervous system, its dysregulation in neurodegenerative diseases, and its potential as a therapeutic target.

Structure and Molecular Architecture

DOT1L is a large protein composed of 1,677 amino acids with a molecular weight of approximately 190 kDa. Its unique architecture distinguishes it from most other histone methyltransferases and underlies its distinctive catalytic mechanism.

Domain Organization

DOT1L possesses a multi-domain structure that enables its diverse functional properties:

N-terminal Chromatin-binding Domain (aa 1-800):

• Contains multiple Alanine/Proline-rich regions
• Mediates chromatin association and nucleosome binding
• Interacts with various chromatin-associated proteins
• Contains binding sites for MLL fusion proteins in leukemia[@okada2005]

• Links N-terminal and C-terminal domains
• Contains residues for protein-protein interactions
• Regulates catalytic activity through allosteric mechanisms

• Contains the S-adenosyl-L-methionine (SAM)-binding pocket
• Catalyzes methyl group transfer to H3K79
• Shares structural similarity with other SAM-dependent methyltransferases
• Contains critical residues for substrate recognition and catalysis[@jones2019]

Structural Features

DOT1L adopts a unique fold that distinguishes it from SET domain methyltransferases:

• The catalytic domain forms a Rossmann-like fold common to SAM-dependent methyltransferases
• A critical "R-loop" structure surrounds the active site
• The enzyme recognizes nucleosomal substrate rather than free histone H3
• H3K79 is located in the histone fold core, requiring nucleosomal access

Post-translational Modifications

DOT1L activity is regulated by several post-translational modifications:

Phosphorylation:

• Casein kinase 2 (CK2) phosphorylation regulates DOT1L chromatin recruitment
• ATM/ATR-mediated phosphorylation in response to DNA damage
• CDK-dependent phosphorylation during cell cycle progression

• p300/CBP-mediated acetylation enhances DOT1L activity
• Histone acetylation facilitates DOT1L access to nucleosomes

• SUMOylation regulates DOT1L protein stability
• Proteasomal degradation controls cellular DOT1L levels

Normal Function in the Nervous System

DOT1L is expressed throughout the brain, with particularly high levels in the cerebral cortex, hippocampus, and cerebellum. Within neurons, DOT1L localizes to both the nucleus and cytoplasm, where it performs essential functions in development and plasticity.

Transcriptional Regulation

H3K79 methylation by DOT1L is associated with actively transcribed genes:

Gene Activation:

• H3K79me2 marks the bodies of actively transcribed genes
• Facilitates RNA polymerase II elongation
• Promotes recruitment of transcription elongation factors
• Regulates tissue-specific gene expression programs[@liu2019]

• Controls timing of neuronal differentiation
• Regulates genes critical for cortical layer formation
• Essential for proper hippocampal development
• Coordinates neurogenesis with migration[@park2010]

DNA Damage Response

DOT1L plays a critical role in the cellular response to DNA damage:

Checkpoint Activation:

• H3K79me2 increases at DNA damage sites
• Facilitates recruitment of 53BP1 and other repair factors
• Promotes non-homologous end joining (NHEJ) repair
• Essential for proper cell cycle arrest after damage[@song2018]

• Maintains telomere structure and function[@eringa2013]
• Prevents transcription-replication conflicts
• Protects against replication stress

Synaptic Plasticity and Learning

DOT1L-mediated H3K79 methylation is increasingly recognized as important for synaptic plasticity and cognitive function:

Long-term Potentiation (LTP):

• H3K79 methylation increases during LTP
• DOT1L is required for memory consolidation
• Regulates expression of synaptic plasticity-related genes[@taya2021]

• DOT1L activity in hippocampus is necessary for spatial learning
• Alters chromatin accessibility at plasticity-related gene promoters
• Required for reconsolidation of memory traces
• Dysregulation leads to cognitive deficits[@chen2023]

Neuronal Development

DOT1L is essential for proper brain development:

Neuronal Migration:

• Regulates genes controlling neuronal migration in the neocortex
• DOT1L deficiency leads to abnormal cortical layering
• Essential for proper positioning of excitatory neurons[@park2010]

• Controls expression of synaptic protein genes
• Regulates postsynaptic density assembly
• Essential for proper dendritic spine development

• DOT1L regulates genes involved in mitochondrial dynamics
• Critical for neuronal energy metabolism[@park2019]
• Protects against metabolic stress

Role in Neurodegenerative Diseases

Dysregulation of DOT1L and H3K79 methylation has been implicated in several neurodegenerative diseases. The epigenetic alterations affect multiple aspects of neuronal function, from gene expression to DNA repair and protein homeostasis.

Alzheimer's Disease

DOT1L and H3K79 methylation are altered in Alzheimer's disease brain:

Epigenetic Dysregulation:

• Global changes in H3K79 methylation patterns in AD brain[@mukherjee2021]
• Altered DOT1L expression in hippocampus and cortex
• Correlation between H3K79 methylation changes and disease severity
• Changes in both H3K79me1 and H3K79me2 levels

• Amyloid-beta accumulation affects DOT1L chromatin targeting
• Tau pathology disrupts DOT1L-mediated transcriptional programs
• Impaired DNA damage response in neurons
• Reduced H3K79 methylation at synaptic plasticity genes[@chen2023]

• DOT1L modulators may restore proper epigenetic balance
• Enhancing DOT1L activity could improve synaptic plasticity
• Combination approaches targeting multiple epigenetic modifications

Parkinson's Disease

Emerging evidence links DOT1L to Parkinson's disease pathology:

Expression Changes:

• Altered DOT1L levels in PD patient brains
• Changes in H3K79 methylation at dopaminergic genes
• Correlation with Lewy body pathology

• DOT1L regulates genes important for dopamine synthesis
• Altered chromatin accessibility in PD models
• Potential involvement in alpha-synuclein expression regulation[@wu2020]

• DOT1L regulates mitochondrial dynamics genes
• Impaired mitochondrial function in PD neurons
• Potential for therapeutic targeting

Aging and Age-Related Neurodegeneration

DOT1L-mediated epigenetic changes are increasingly recognized as a hallmark of brain aging:

Age-Associated Changes:

• Progressive alterations in H3K79 methylation during aging
• "Epigenetic drift" affects neuronal gene expression
• Reduced H3K79me2 at synaptic plasticity genes
• Accumulation of DNA damage with impaired repair[@huang2023]

• Decline in synaptic plasticity and cognitive function
• Increased genomic instability
• Impaired mitochondrial function
• Altered stress response pathways

Other Neurological Disorders

Huntington's Disease:

• Altered H3K79 methylation in HD models
• Changes in DOT1L expression
• Potential involvement in mutant huntingtin pathology

• Dysregulated H3K79 methylation in motor neurons
• Altered DNA damage response pathways
• Potential therapeutic target

• DOT1L mutations cause neurodevelopmental phenotypes
• Implicated in intellectual disability and autism
• Essential for proper brain development

Interaction Network

DOT1L interacts with numerous proteins to perform its cellular functions:

Core Chromatin Complexes

| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|-------------------|------------------------|
| MLL1/MLL2 | Direct binding | Recruitment to specific gene loci |
| AF4/AF9/ENL | MLL fusion proteins | Leukemogenic transformation |
| p300/CBP | Acetyltransferase complex | Enhanced catalytic activity |
| DOT1L-associated proteins | Direct interaction | Chromatin targeting |

DNA Repair Factors

| Repair Protein | Interaction | Pathway |
|----------------|-------------|---------|
| 53BP1 | H3K79me-dependent | NHEJ repair |
| ATM | Phosphorylation cascade | DNA damage response |
| MDC1 | Direct binding | Checkpoint activation |

Transcriptional Regulators

| Factor | Mechanism | Effect |
|--------|-----------|--------|
| RNA Pol II | Co-transcriptional | Elongation |
| TFIID | Direct interaction | Transcription initiation |
| SIRT1 | Deacetylase regulation | Activity modulation |

Therapeutic Targeting

DOT1L represents a promising therapeutic target for both cancer and neurodegenerative diseases. The development of selective DOT1L inhibitors has progressed significantly in recent years.

DOT1L Inhibitors in Development

Epizyme (EPZ-5676/Pinometostat):

• First clinical-stage DOT1L inhibitor
• Demonstrated efficacy in MLL-rearranged leukemia
• Showed target engagement in clinical trials

• Improved potency and selectivity
• Better pharmacokinetic properties
• Reduced off-target effects[@li2021]

Neurodegenerative Disease Applications

Alzheimer's Disease:

• Enhancing DOT1L activity to improve synaptic plasticity
• Restoring proper H3K79 methylation patterns
• Combination with other epigenetic therapies[@morrison2022]

• Modulating DOT1L to protect dopaminergic neurons
• Targeting mitochondrial function
• Enhancing DNA repair capacity

• "Epigenetic rejuvenation" approaches
• Restoring youthful methylation patterns
• Protecting cognitive function[@zhao2022]

Challenges and Considerations

Selectivity:

• Ensuring specificity for DOT1L over other methyltransferases
• Achieving proper tissue distribution to the brain
• Balancing efficacy with toxicity

• Too much or too little DOT1L activity can be harmful
• Need for precise dosing and timing
• Patient-specific considerations

• Crossing the blood-brain barrier
• Targeting specific brain regions
• Cell-type specific delivery

Animal Models and Research Findings

Knockout Mouse Models

DOT1L Conditional Knockout:

• Embryonic lethal in complete knockout
• Neural-specific knockout leads to developmental defects
• Deficits in neuronal migration and cortical layering[@park2010]

• Viable with subtle phenotypic changes
• Enhanced susceptibility to leukemogenesis
• Mild cognitive deficits

Pharmacological Studies

• DOT1L inhibitors show activity in leukemia models
• Epigenetic modulators alter H3K79 methylation in brain
• Therapeutic effects in Alzheimer's disease models

Future Directions and Open Questions

Research Priorities

Unresolved Questions

• What are the precise molecular mechanisms of DOT1L in memory formation?
• How do different disease states alter DOT1L function?
• Can DOT1L modulation safely achieve therapeutic benefits in neurodegeneration?
• What is the full extent of DOT1L's role in aging?

See Also

• [DOT1L Gene](/genes/dot1l)
• [Histone Modifications](/entities/histone-modifications)
• [Epigenetic Regulation](/mechanisms/epigenetic-regulation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response)
• [MLL Leukemia](/diseases/mll-leukemia)
• [Chromatin Remodeling](/mechanisms/chromatin-remodeling)

External Links

• [UniProt: DOT1L (Q8TEZ3)](https://www.uniprot.org/uniprot/Q8TEZ3)
• [NCBI Gene: DOT1L](https://www.ncbi.nlm.nih.gov/gene/83440)
• [PDB: DOT1L Structures](https://www.rcsb.org/)
• [PubMed: DOT1L Research](https://pubmed.ncbi.nlm.nih.gov/?term=DOT1L+histone+methyltransferase)